UFT経口投与と膀胱内注入化学療法による表在性膀胱腫瘍の再発予防効果の検討

Abstract

1)表在性膀胱腫瘍のTUR後の再発予防を目的に, TUR後1週目よりの抗癌剤の膀胱内注入療法に加え, 6ヵ月間400 mg/dayのUFTの経口投与を行った.2)全適格例でのTUR後2年の無再発率曲線の比較では, UFT投与による効果は認めなかった.3)しかし, 再発例や, さらに再発かつ多発症例で比較すると, UFT投与群で無再発率が良好な傾向が認められた

The influence of N1-(2-tetrahydrofuryl)-5-fluorouracil plus uracil (UFT) on the recurrence of superficial bladder tumors was evaluated in a randomized clinical study. Group A (n = 196) underwent transurethral resection (TUR) and the intravesical chemoprophylaxis, while group B (n = 193) received 400 mg per a day of UFT orally for 6 months in addition to the instillation therapy. These adjuvant therapy was started one week after TUR. Consequently, 30 patients in group B showed UFT-related toxicity and administration of UFT was discontinued in 10 of them. In addition, 87 patients in group B did not complete the 6-month course of UFT administration. Comparison of 2-year actuarial non-recurrence curves revealed no significant difference between groups A and B. However, UFT seemed to have a favorable prophylactic effect when recurrence rates were compared among those patients with recurrent tumors (generalized Wilcoxon: p = 0.1277), and those with recurrent multiple tumors (p = 0.0847).